ResMed names Sandeep Gulati as new General Manager, South Asia

Published On 2022-11-16 08:00 GMT   |   Update On 2022-11-16 15:34 GMT
Advertisement

New Delhi: ResMed has announced the appointment of Sandeep Gulati as General Manager, South Asia. In his new role, Sandeep will be responsible for further growth in India market and ensuring that there is increased awareness about sleep and respiratory disorders.

A seasoned and dynamic professional, Sandeep brings a rich twenty-three-year-long experience of leading Sales and Marketing organizations in the pharmaceuticals and medical device industry. Sandeep has been a part of ResMed since 2020 and will now be leading from the front. In his two years at ResMed as Sales Head – India & South Asia, his long-term vision and strategy led ResMed to achieve strong business results in a short span of time. Sandeep has previously worked in various assignments in Sales & Marketing in Novartis & Baxter for a major part of his career.

Advertisement

Congratulating Sandeep on his new appointment, Carlos Montiel, Vice-President, LATAM & South Asia said "I welcome Sandeep to his new role. He has very quickly established himself as a strong leader with impeccable business acumen. His analytical approach and consequent strategic thinking has helped achieve great results, such as increased reach in the marketplace, improved product mix for connected care offerings, and alternate opportunities for business growth. He is an innovative, collaborative, and dedicated industry leader who always puts the needs of consumers and fellow ResMedians first along with being an incredible human being. I wish him success with his new responsibilities."

Expressing gratitude on his appointment, Sandeep said, "I am delighted and humbled to be given this responsibility to steer the organization to fulfill its mission of delivering life-changing, digitally connected health solutions to patients with respiratory issues. India remains a highly undiagnosed market with 29 million individuals affected by obstructive sleep apnea, and all my efforts will continue to be aligned with ResMed's endeavour to offer out-of-hospital solutions so that more people can be treated. We will remain dedicated to delivering more personalized care, measurable results, and improved health outcomes."

Read also: ResMed to acquire MEDIFOX DAN for USD 1 billion

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News